Accutane Dosage Guide: How Much, How Long & Side Effects

*By the BestMedCal editorial team ·Last updated October 2026*

Quick answer: Accutane (isotretinoin) is dosed by body weight, usually 0.5–1.0 mg/kg a day for a standard course, building toward a cumulative total of about 120–150 mg/kg. A typical course runs four to six months, though low-dose plans stretch longer for a gentler ride. Your dermatologist sets the exact dose.

Isotretinoin is the most effective treatment for severe, stubborn acne — and also the most misunderstood. Much of the fear online dates to the 1980s or to case reports that larger studies never confirmed. This guide sticks to what current, sourced evidence actually shows, from how the drug works to the doses, timeline, side effects and the questions people ask most. To work out your own numbers as you read, open the Accutane Cumulative Dose Calculator.

Accutane is the best-known brand name for isotretinoin, a vitamin A derivative that belongs to the retinoid family. Doctors prescribe it for severe, treatment-resistant acne that gentler options have failed to clear (AAD Acne Guidelines, 2024). It is taken as soft gelatin capsules, most often in 10, 20 and 40 mg strengths, with some brands adding a 5 mg size.

The retinoid label explains both its power and its precautions. As a concentrated form of vitamin A, the drug acts deep inside the oil glands rather than on the surface, which is how it reaches cystic acne that creams and antibiotics leave behind. That same potency is why dosing is weight-based and closely monitored throughout the course — the same weight-based dosing method used across other medicines.

Many people enjoy lasting, often permanent clearance afterwards — but that outcome is not guaranteed for life, and a minority relapse and repeat the course later.

Isotretinoin is so effective because it tackles every root cause of acne at once. To see how, it helps to know the three drivers behind a breakout:

A person can have one, two, or all three of these at the same time.

Most treatments only reach a single piece of that puzzle:

Oral isotretinoin stands apart because it works on every level. It does this on three fronts:

The combined result is calmer skin with far less inflammation and noticeably reduced redness (AAD Acne Guidelines, 2024).

Low-dose and standard-dose Accutane reach the same cumulative target by different paths, so the real decision is pace versus comfort, not strength versus weakness. A standard schedule clears skin quickly on a shorter course, while a low-dose plan moves gently over a longer stretch. Both finish at the identical total.

Two rows carry the real reassurance. Whichever pace you pick, the safety monitoring is identical — the same blood work and pregnancy-prevention rules apply throughout. And on relapse, recent evidence is clear: once the cumulative goal is reached, the daily speed barely moves the odds of acne returning (JAMA Dermatology, 2025).

So the choice comes down to your life, not your outcome. A faster course rewards anyone who wants results sooner and can handle stronger side effects, while an extended plan suits those who would rather trade time for an easier ride.

Oiliness usually drops within the first 2–4 weeks, and visible improvement in spots typically begins between weeks four and eight. Skin often keeps clearing for a while after the medication stops, so the drug works gradually, not overnight. Roughly 85% of patients respond inside a four-month course, while around 15% need longer — occasionally up to ten months, often because of deep macrocomedones or a hormonal driver (AAD Acne Guidelines, 2024).

A standard course runs about four to six months (16–24 weeks), long enough to reach a cumulative dose near 120–150 mg/kg. (New to these units? See mg/kg/day vs mg/kg per dose.) A low-dose plan covers the same total more slowly, often over twelve to eighteen months. Either way, the finish line is clinical: treatment continues until the skin is clear and then for a month or two more, rather than stopping at a fixed number.

Isotretinoin is powerful, and like any potent medicine it carries possible side effects. The long list can look alarming, but most are predictable, dose-related and reversible, and they ease with a few simple habits.

The more common, milder effects show up on the skin and membranes:

The less common but more serious ones need monitoring rather than panic:

By system, the typical picture looks like this:

A calculator sizes your dose, but staying comfortable on the course comes down to daily habits:

Three products do the job: a gentle, non-foaming cleanser, a non-comedogenic moisturiser, and an oil-free SPF 30+ sunscreen — while everything acidic or exfoliating comes off the shelf until the course ends.

No. It does curb acne bacteria by removing the oil they feed on, but that is a side effect of its action, not an antibiotic mechanism — so it is not classed as one.

For most moderate acne, yes — it simply takes longer. In a prospective study of 150 patients given a fixed 10 mg daily until a cumulative dose of 90–110 mg/kg, every patient reached total clearance at a mean of 24 weeks, with mild relapse in only 4%. Severe cases cleared more slowly, at 32.9 weeks against 19.1 for milder acne (J Cosmet Dermatol, 2017). The real driver of lasting remission is how long the oil glands stay suppressed, not the daily milligram count.

An early flare is real, but far from universal. Studies report an initial flare in up to about 32% of patients during the first month, usually mild to moderate (Eur J Dermatol, 2008). It shows up most in severe inflammatory cystic acne, and starting at a lower dose — or adding a short course of prednisone early — can blunt it. A flare is not proof the drug is working, so report it: an untreated severe flare can scar.

The long-term picture is reassuring. In a propensity-matched analysis of 61,894 pairs followed for six to ten years, isotretinoin showed no increased risk of inflammatory bowel disease (HR 0.88) or ulcerative colitis, and lipid rises were transient (J Drugs Dermatol, 2025). The truly permanent risks are narrow and avoidable: fetal malformation from pregnancy exposure, and scarring from waxing — so waxing is off-limits during treatment and for six months afterwards.

At the population level, the data are reassuring. A meta-analysis of 25 studies covering 1,625,891 participants found the one-year absolute risk of completed suicide, suicide attempt, suicidal ideation and self-harm each under 0.5%, and depression at 3.83% — with no increased relative risk of psychiatric disorders overall (JAMA Dermatology, 2024). That reassurance is not personal immunity: clinicians still screen every patient for mood changes, any new shift should be reported promptly, and anyone struggling should reach out for support without delay.

Hair loss is uncommon and usually temporary. A review of 22 studies found shedding in 3.2% of patients on under 0.5 mg/kg/day, rising to 5.7% on 0.5 mg/kg/day or more (JAAD International, 2022). The pattern is telogen effluvium — diffuse, non-scarring shedding — and because the follicles are not damaged, regrowth is expected over roughly three to twelve months after stopping.

For a minority, yes. Among 19,907 people who completed a course, 22.5% relapsed and 8.2% needed a second round, with a median time to relapse of 7.5 months; a higher cumulative dose was linked to lower rates of both (JAMA Dermatology, 2025). The most useful lever afterwards is maintenance — starting a topical retinoid once the course ends is the main modifiable step for holding a remission.

There is no withdrawal syndrome and no taper is needed, but relapse becomes more likely. In a study of 212 patients the overall relapse rate was 37.3%, higher in those who still had residual lesions at the end (Dermatologic Therapy, 2021). Stopping early can still be the right call for marked liver-enzyme or triglyceride rises, a severe headache, or intolerable side effects — a clinical decision, not a failure, and the course can usually be restarted later.

Stop the medication at once and contact the prescriber — pregnancy is an absolute contraindication. The FDA label directs that isotretinoin be discontinued immediately and the patient referred to an obstetrician experienced in reproductive toxicity. Major congenital malformations, spontaneous abortion and premature birth have all been documented, which is why prevention is strict: two forms of contraception from a month before treatment to a month after the last dose, monthly pregnancy testing, and no blood donation during the course or for a month afterwards.

Current expert consensus supports it, despite the older six-month rule. A systematic review found insufficient evidence to justify delaying laser hair removal, fractional ablative and non-ablative lasers, superficial chemical peels, or minor surgery for patients on — or just off — isotretinoin (JAMA Dermatology, 2017). Mechanical dermabrasion and fully ablative resurfacing remain the exceptions to avoid. The FDA insert still advises a six-month wait, so confirm with your own dermatologist before booking.

The endpoint is clinical, not arithmetic. Treatment continues until the skin is clear of active inflammatory acne, then carries on for at least one further month — often one to two — before stopping. The familiar 120–150 mg/kg range is a planning guide, not a finish line: the 2025 EuroGuiDerm update states that an evidence-based cumulative-dose target for preventing relapse cannot currently be defined (EuroGuiDerm, 2025).

This guide is for general education and does not replace a professional assessment. Isotretinoin is a potent prescription medicine with serious risks, including severe birth defects, and must be taken only under a dermatologist's supervision. Always follow your prescriber's dosing and monitoring instructions, and raise any concern — physical or emotional — with them first. If you ever have thoughts of self-harm, contact your doctor or local emergency services straight away.